Table 2.
Assessment of the prevalence of immunosuppression among COVID‐19 infected patients (I 2 = 93%, P < 0.00001)
| Author | Sample | Observed patients receiving immunosuppression | Expected patients receiving immunosuppression | The observed prevalence of immunosuppression (%) | Weight (%) | Observed to expected ratio (95% confidence interval) |
|---|---|---|---|---|---|---|
| Guan et al. 21 | 1099 | 2 | 29.67 | 0.182 (2/1099) | 16.3 | 0.07 (0.03–0.15) |
| Jin et al. 22 | 651 | 1 | 17.58 | 0.154 (1/651) | 16.0 | 0.06 (0.02–0.13) |
| Lian et al. 23 | 788 | 1 | 21.28 | 0.127 (1/788) | 15.5 | 0.05 (0.02–0.12) |
| Liang et al. 24 | 1590 | 2 | 42.93 | 0.126 (2/1590) | 15.4 | 0.05 (0.02–0.12) |
| Richardson et al. 25 | 5700 | 55 | 153.90 | 0.96 (55/5700) | 18.3 | 0.36 (0.26–0.50) |
| Zhang et al. 26 | 221 | 3 | 5.97 | 1.357 (3/221) | 18.5 | 0.5 (0.38–0.66) |
| Total | 10 049 | 64 | 271.32 | 0.637 (64/10049) | 100% | 0.12 (0.05– 0.27) |